Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Business & Industry
- Roche opens access to pathology imaging tools to improve patient care
- Pfizer and BioNTech submit a variation to EMA with the data in support of a booster dose of COMIRNATY®
- Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
- SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
- Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders
Research & Development
- COVID-19 nasal vaccine candidate effective at preventing disease transmission
- How a plant virus could protect and save your lungs from metastatic cancer
- Scientific evidence to date on COVID-19 vaccine efficacy does not support boosters for general population
- NIH scientists build a cellular blueprint of multiple sclerosis lesions
- First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
- No serious health effects linked to mRNA COVID-19 vaccines
- Blood vessels produce growth factor that promotes metastases
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA advances data, IT modernization efforts with new office of digital transformation
- ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines
- FDA approves first COVID-19 vaccine
- FDA approves new treatment for Pompe disease
- FDA approves first interchangeable biosimilar insulin product for treatment of diabetes